Login to Your Account



Search

Search results

Pharma: clinic roundup

Pfizer Inc. , of New York, and Bristol-Myers Squibb Co. , also of New York, said results of a pre-specified subanalysis of the phase III ARISTOTLE trial assessing the effect of blood pressure control on outcomes as well as the treatment effect of ...

BioWorld Today - Staff - 2014-03-28 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Pfizer Inc ., of New York, reported top-line results from a phase IIIB study evaluating the 24-month efficacy of Genotropin (somatropin) on the height in small-for-gestational-age children 24-30 months old. (BioWorld-Today-2014-03-27) ...

BioWorld Today - Staff - 2014-03-27 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Pfizer Inc. , of New York, reported that PROFILE 1014, a phase III study testing anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) met its primary objective of significantly prolonging progression-free survival in previously untreated p ...

BioWorld Today - Staff - 2014-03-26 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Abbvie Inc. , of North Chicago, Ill., said a pivotal phase III trial that will evaluate the use of Humira (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, has been initiated. ...

BioWorld Today - Staff - 2014-03-21 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Novo Nordisk A/S , of Bagsvaerd, Denmark, reported positive results from pathfinder2, the first phase III trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for hemophilia A patients. (BioWorld-Today-2014-03-20) ...

BioWorld Today - Staff - 2014-03-20 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Ipsen SA , of Paris, reported phase IIa results showing that Dysport was associated with a mean reduction from baseline of urinary incontinence episodes greater than 75 percent, 12 weeks after injection, regardless of how the drug was administered in ...

BioWorld Today - Staff - 2014-03-19 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Astrazeneca plc , of London, (AZN) said patient enrollment was completed approximately four months ahead of plan in the phase III trial EUCLID studying Brilinta (ticagrelor) tablets. (BioWorld-Today-2014-03-18) ...

BioWorld Today - Staff - 2014-03-18 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Glaxosmithkline plc (GSK), of London, said a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reducing the frequency of exacerbations in patients with severe eosinophilic ast ...

BioWorld Today - Staff - 2014-03-14 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Pfizer Inc. , of New York, reported that detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults, or CAPiTA, which enrolled approximately 85,000 subjects, demonstrated that Prevenar 13 (pneumococcal polysaccharide conjugat ...

BioWorld Today - Staff - 2014-03-13 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported results from the phase III STARTVerso 4 trial in patients co-infected with hepatitis C virus (HCV) and HIV, showing that HCV cure 12 weeks (SVR12) after the conclusion of treatment was ach ...

BioWorld Today - Staff - 2014-03-07 01:00 - 0 comments - 0 attachments